Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
2.370
-0.040 (-1.66%)
At close: Dec 5, 2025, 4:00 PM EST
2.469
+0.099 (4.19%)
After-hours: Dec 5, 2025, 7:35 PM EST
Acrivon Therapeutics Stock Forecast
ACRV's stock price has decreased by -64.78% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Acrivon Therapeutics stock have an average target of 14.67, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 518.99% from the current stock price of 2.37.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +701.69% | Nov 25, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +237.55% | Aug 14, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +279.75% | May 15, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 → $10 | Buy | Maintains | $18 → $10 | +321.94% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
169.02K
Revenue Next Year
1.53M
from 169.02K
Increased by 805.20%
EPS This Year
-2.11
from -2.38
EPS Next Year
-2.01
from -2.11
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.2M | 11.0M | ||||
| Avg | 169,024 | 1.5M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 6,422.7% | ||||
| Avg | - | 805.2% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.09 | -1.50 | ||||
| Avg | -2.11 | -2.01 | ||||
| Low | -2.13 | -2.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.